GS4 · UPSC Mains

MedPharm Ltd. is a reputed pharmaceutical company known for manufacturing affordable generic medicines. Its products are distributed nationwide through both private channels and government procurement programs. The company is preparing for a major IPO within the next six months. In early March, a government hospital in a Tier-2 city reports that patients administered MedPharm's widely used antibiotic "Xefamed" developed severe adverse reactions, including two fatalities. Initial reports are shared with the company's regional distributor, but no formal escalation is made to corporate headquarters. Meanwhile, an internal quality assurance report, reviewed two weeks earlier, had flagged inconsistencies in the production batch linked to the hospital. However, the senior leadership team decided not to halt distribution, citing the urgency of meeting large state government orders and avoiding disruption in rural health schemes. A mid-level Quality executive, disturbed by the silence, emails the CEO and threatens to alert external regulators and the media. The company's legal and PR teams convene an emergency meeting. The advice is to deny any link until lab results are conclusive, and to describe it publicly as an "isolated incident under internal review." Behind closed doors, the senior leadership considers quietly recalling the batch from urban private pharmacies - where consumer awareness is high - while continuing distribution through public hospitals, citing that "the public health ecosystem cannot afford panic." The ethics & compliance officer voices concerns about this approach, but is told not to "interfere in operational strategy." At this point, a popular journalist contacts the company with a leaked version of the Quality report. The board is informed and is deeply concerned about negative media coverage impacting the IPO. There is no final proof that the drug caused the deaths, but the circumstantial link is strong, and internal records show prior awareness. Questions. (a) What are the key ethical issues and lapses evident in the case? (b) What are the options available to the company's leadership? Evaluate them in terms of public accountability and stakeholder impact. (c) If you were the CEO what course of action would you recommend and why? (Answer in 250 words)

20 marks · 250 words · 5 toppers answered this

GS4 · Case studies on the above issues

See this question on Topper's Copy by Hashin →

More GS4 questions →